First-to-First GLP-1 Launches New Clinical Trial of “Head-to-Head” Semaglutide

July 21, 2025 Source: drugdu 146

Sciwind Biopharma has registered a new clinical trial on the Drug Clinical Trial Registration and Information Disclosure Platform: a multicenter, randomized, open-label, switch treatment phase II study (SLIMMER-UP-SWITCH) on the efficacy and safety of XW003 injection versus semaglutide injection in obese patients. If the Phase II results are positive, it will further verify the clinical advantages of its world-first cAMP-biased GLP-1 mechanism and accelerate its impact on the 100 billion weight loss market.